Serum hypoxia-inducible factor-2: A candidate prognostic biomarker for laryngeal cancer

Simple item page
dc.contributor.authorEskiizmir G.
dc.contributor.authorÇalıbaşı Koçal G.
dc.contributor.authorUysal T.
dc.contributor.authorEllidokuz H.
dc.contributor.authorBaşpınar Y.
dc.date.accessioned2024-07-22T08:05:29Z
dc.date.available2024-07-22T08:05:29Z
dc.date.issued2021
dc.description.abstractObjectives: To determine the serum hypoxia-inducible factor-1, -2 and -3 (HIF-1, -2 and -3) levels in patients with laryngeal neoplasm, and to investigate their role in differential diagnosis, prediction of tumour characteristic and extension, and prognosis and survival. Study Design: Prospective, cohort study at a tertiary referral centre. Settings: The study was conducted in a tertiary medical centre. Participants: Patients with benign, premalignant and malignant laryngeal neoplasms were included. Sixty-four patients with a laryngeal neoplasm were enrolled. Main Outcome Measures: Serum HIF-1, -2 and -3 levels were measured from blood samples that were drawn before treatment, using ELISA. Results: A statistically significant difference between benign (HIF-1, -2, -3:4046,1 pg/mL; 2581,5 pg/mL; 1321,0 pg/mL), premalignant (HIF-1, -2, -3:3630,3 pg/mL; 3229,7 pg/mL; 2549,8 pg/mL) and malignant (HIF-1, -2, -3:3576,7 pg/mL; 2595,8 pg/mL; 1106,3 pg/mL) laryngeal neoplasms was not detected when serum HIF-1, -2 and -3 levels were compared. However, high serum HIF-2 level adversely affected survival and locoregional control and had more than 7-fold increase in hazard ratio. Moreover, serum HIF-2 was an independent prognostic factor for 2-year overall, disease-free, distant metastasis-free survival and locoregional control. Conclusion: This is the first clinical study in which the diagnostic, predictive and prognostic roles of hypoxia-related biomolecules were examined in laryngeal neoplasms. Hypoxia-inducible factor-2 is a prognostic factor in larynx cancer irrespective of treatment modality. © 2021 John Wiley & Sons Ltd.
dc.identifier.DOI-ID10.1111/coa.13789
dc.identifier.issn17494478
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/13160
dc.language.isoEnglish
dc.publisherJohn Wiley and Sons Inc
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectBasic Helix-Loop-Helix Transcription Factors
dc.subjectBiomarkers, Tumor
dc.subjectCohort Studies
dc.subjectDisease-Free Survival
dc.subjectFemale
dc.subjectHumans
dc.subjectHypoxia
dc.subjectLaryngeal Neoplasms
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPrognosis
dc.subjectProspective Studies
dc.subjecthypoxia inducible factor
dc.subjecthypoxia inducible factor 1
dc.subjecthypoxia inducible factor 2
dc.subjecthypoxia inducible factor 3
dc.subjecttumor marker
dc.subjectunclassified drug
dc.subjectbasic helix loop helix transcription factor
dc.subjecttumor marker
dc.subjectadult
dc.subjectanemia
dc.subjectArticle
dc.subjectcancer prognosis
dc.subjectcancer survival
dc.subjectclinical feature
dc.subjectdiagnostic value
dc.subjectdifferential diagnosis
dc.subjectdisease association
dc.subjectdisease free survival
dc.subjectdistant metastasis free survival
dc.subjectenzyme linked immunosorbent assay
dc.subjectfemale
dc.subjecthuman
dc.subjectlarynx cancer
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectoverall survival
dc.subjectpredictive value
dc.subjectprospective study
dc.subjectprotein blood level
dc.subjectprotein function
dc.subjectsurvival time
dc.subjecttertiary care center
dc.subjecttumor invasion
dc.subjectaged
dc.subjectblood
dc.subjectcohort analysis
dc.subjecthypoxia
dc.subjectlarynx tumor
dc.subjectmiddle aged
dc.subjectprognosis
dc.subjectvery elderly
dc.titleSerum hypoxia-inducible factor-2: A candidate prognostic biomarker for laryngeal cancer
dc.typeArticle

Files

Collections

Scopus Koleksiyonu